Seeking Alpha

Regeneron's Eylea boosts sight in those with diabetic ailment

  • Regeneron Pharmaceuticals' (REGN) Eylea treatment was significantly more successful than laser surgery in improving the vision of patients with diabetic macular edema (DME) in two Phase III trials.
  • DME is the leading cause of blindness in younger and middle-aged adults; Eylea could potentially treat over 6M patients globally.
  • Regeneron intends to apply for FDA approval of Eylea to treat DME in 2013, a year ahead of plan. Bayer, which sells the drug outside the U.S., will apply for EU authorization.
  • Eyelea is already used in patients with wet age-related macular edema, the leading cause of blindness among the elderly. (PR)
  • Regeneron earnings
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs